Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity
Science · 25.04.2025 · 388 (6745)
DOI: 10.1126/science.adr3026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 25.04.2025. Verfasst von David Kung-Chun Chiu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University, Stanford, CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Erythropoietin, Liver Neoplasms, Receptors, Erythropoietin. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Successful cancer immunotherapy requires a patient to mount an effective immune response against tumors; however, many cancers evade the body’s immune system. To investigate the basis for treatment failure, we examined spontaneous mouse models of hepatocellular carcinoma (HCC) with either an inflamed T cell–rich or a noninflamed T cell–deprived tumor microenvironment (TME). Our studies reveal that erythropoietin (EPO) secreted by tumor cells determines tumor immunotype. Tumor-derived EPO autonomously generates a noninflamed TME by interacting with its cognate receptor EPOR on tumor-associated macrophages (TAMs). EPO signaling prompts TAMs to become immunoregulatory through NRF2-mediated heme depletion. Removing either tumor-derived EPO or EPOR on TAMs leads to an inflamed TME and tumor regression independent of genotype, owing to augmented antitumor T cell immunity. Thus, the EPO/EPOR axis functions as an immunosuppressive switch for antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University, Stanford, CA, USA.
- Stanford Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, USA.
- Advanced Drug Delivery and Regenerative Biomaterials Laboratory, Cardiovascular Institute, Department of Medicine, Stanford University, Stanford, CA, USA.
- ImmunEdge Inc., Mountain View, CA, USA.
- Laboratory of Membrane Biology, New York Blood Center, New York, NY, USA.
- Department of Otolaryngology-Head and Neck Surgery, Stanford University, Stanford, CA, USA.
ORCID-Profile: David Kung-Chun Chiu, Bowie Yik-Ling Cheng, Kazukuni Hayashi, Bo Yu, Ryan Lee, Catherine Zhang, Nathan E Reticker-Flynn, Edgar G Engleman
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Chiu, D. K., Zhang, X., Cheng, B. Y., Liu, Q., Hayashi, K., Yu, B., Lee, R., Zhang, C., An, X., Rajadas, J., Reticker-Flynn, N. E., Rankin, E. B., & Engleman, E. G. (2025). Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity. Science, 388(6745). https://doi.org/10.1126/science.adr3026
Vancouver
Chiu DK, Zhang X, Cheng BY, Liu Q, Hayashi K, Yu B, et al. Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity. Science. 2025;388(6745). doi:10.1126/science.adr3026
BibTeX
@article{Chiu2025,
author = {Chiu, David Kung-Chun and Zhang, Xiangyue and Cheng, Bowie Yik-Ling and Liu, Qiang and Hayashi, Kazukuni and Yu, Bo and Lee, Ryan and Zhang, Catherine and An, Xiuli and Rajadas, Jayakumar and Reticker-Flynn, Nathan E and Rankin, Erinn B and Engleman, Edgar G},
title = {Tumor-derived erythropoietin acts as an immunosuppressive switch in cancer immunity},
journal = {Science},
year = {2025},
volume = {388},
number = {6745},
doi = {10.1126/science.adr3026}
}
EUVIMED